PLATINOL-AQ Drug Patent Profile

Which patents cover Platinol-aq, and what generic alternatives are available?

Platinol-aq is a drug marketed by Hq Spclt Pharma and is included in one NDA.

The generic ingredient in PLATINOL-AQ is cisplatin. There are fourteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the cisplatin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Platinol-aq

A generic version of PLATINOL-AQ was approved as cisplatin by PHARMACHEMIE BV on May 16^th, 2000.

Summary for PLATINOL-AQ

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	22
Clinical Trials:	343
DailyMed Link:	PLATINOL-AQ at DailyMed

Recent Clinical Trials for PLATINOL-AQ

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Regeneron Pharmaceuticals	Phase 2
AstraZeneca	Phase 3
Wuhan Union Hospital, China	Phase 2

See all PLATINOL-AQ clinical trials

Pharmacology for PLATINOL-AQ

Drug Class

Platinum-based Drug

US Patents and Regulatory Information for PLATINOL-AQ

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hq Spclt Pharma	PLATINOL-AQ	cisplatin	INJECTABLE;INJECTION	018057-003	Jul 18, 1984		DISCN	Yes	No

Expired US Patents for PLATINOL-AQ

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Hq Spclt Pharma	PLATINOL-AQ	cisplatin	INJECTABLE;INJECTION	018057-003	Jul 18, 1984
Hq Spclt Pharma	PLATINOL-AQ	cisplatin	INJECTABLE;INJECTION	018057-003	Jul 18, 1984
Hq Spclt Pharma	PLATINOL-AQ	cisplatin	INJECTABLE;INJECTION	018057-003	Jul 18, 1984

International Patents for PLATINOL-AQ

See the table below for patents covering PLATINOL-AQ around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	149192
Australia	4383379
France	2427097
Norway	790313
Hungary	177557	PROCESS FOR PREPARING STABLE AEQUOUS STERILE SOLUTION OF CYS-PLATINIC/II/-DIAMINE-DICHLORIDE
South Africa	7900395
Finland	66121

PLATINOL-AQ Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for PLATINOL-AQ

Introduction

PLATINOL-AQ, also known as cisplatin, is a platinum-based chemotherapy drug widely used in the treatment of various types of cancer, including bladder, testicular, and ovarian cancers. Here, we delve into the market dynamics and financial trajectory of this critical oncology drug.

Market Size and Growth

The oncology drugs market, which includes PLATINOL-AQ, is poised for significant growth. By 2031, the global oncology drugs market is projected to reach USD 532.91 billion, growing at a CAGR of 12.6% from 2024 to 2031[1].

Key Drivers

Several factors drive the demand for PLATINOL-AQ and other oncology drugs:

• Increasing Cancer Prevalence: The rising global incidence of cancer is a primary driver. According to the World Health Organization (WHO), cancer is the second leading cause of death worldwide[1].
• Adoption of Targeted Therapies: The increasing adoption of targeted therapies and immunotherapies, which often include platinum-based drugs like PLATINOL-AQ, contributes to market growth[1].
• Advancements in Medical Science: Decades of significant investments in medical science, biotechnology, and oncology have made platinum drugs integral to cancer treatment, resulting in substantial market gains[4].

Market Trends

• Regional Dominance: North America is anticipated to retain a higher market share due to increased disease prevalence, advanced healthcare infrastructure, and higher national disposable income[4].
• Emergence of Analog Drugs: The development of analog drugs, such as carrier molecule platinum complexes, aims to overcome drug resistance in cancer cells, which could further boost the market for platinum-based drugs like PLATINOL-AQ[4].

Pricing Dynamics

The pricing of anticancer drugs, including PLATINOL-AQ, has been a subject of scrutiny:

• Increasing Launch Prices: The average launch price of anticancer drugs, adjusted for inflation and health benefits, has increased by 10% annually from 1995 to 2013. This trend is expected to continue, driven by institutional features of the market that allow manufacturers to set prices at or slightly above those of existing therapies[3].
• Example of High Pricing: For instance, Bristol-Myers Squibb's melanoma drug ipilimumab (Yervoy) was launched at $120,000 for a course of therapy, highlighting the high pricing strategy in the oncology market[3].

Financial Trajectory

• Revenue Forecast: The financial trajectory for PLATINOL-AQ is closely tied to the overall oncology drugs market. With the market expected to grow significantly, the revenue from PLATINOL-AQ is likely to increase, although specific financial projections for the drug are not available.
• Cost and Pricing Strategies: Pharmaceutical companies often balance the high development costs of drugs like PLATINOL-AQ with pricing strategies that ensure profitability. The high launch prices of new anticancer drugs help offset the costs and maintain profitability[3].

Challenges and Limitations

Despite the growth potential, there are several challenges and limitations:

• Adverse Side Effects: PLATINOL-AQ is associated with significant side effects, including nephrotoxicity, ototoxicity, and myelosuppression. These adverse effects can limit its use, especially in elderly patients and those with pre-existing conditions[2][5].
• Drug Resistance: The development of resistance to platinum-based drugs is a major limitation. New age drug resistance capabilities of cancerous cells can downplay the efficacy of these drugs, potentially restraining market growth in low-income economies[4].
• Regulatory Hurdles: Stringent government regulations and the need for careful monitoring and management of side effects add to the complexity and cost of using PLATINOL-AQ[1].

Competitive Landscape

The market for platinum-based drugs is competitive, with several key players:

• Major Players: Companies like Qilu Pharmaceuticals Ltd., Dr. Reddy’s Lab, Accord Healthcare, and Novartis AG are significant players in the platinum-based drugs market[4].
• Market Share: The competitive intensity and market share distribution among these players are influenced by factors such as product portfolio, pricing strategies, and regional presence.

Future Outlook

The future outlook for PLATINOL-AQ is promising but complex:

• Innovation and R&D: Continued innovation in the development of analog drugs and strategies to overcome drug resistance will be crucial for maintaining market growth[4].
• Healthcare Infrastructure: The expansion of healthcare infrastructure, particularly in developing regions, will increase access to these drugs and drive market growth[4].

Key Takeaways

• The oncology drugs market, including PLATINOL-AQ, is expected to grow significantly due to increasing cancer prevalence and advancements in medical science.
• Pricing dynamics are influenced by high launch prices and the need to balance development costs with profitability.
• Adverse side effects and drug resistance are major challenges that need to be addressed.
• The competitive landscape is dominated by several key players, and future growth will depend on innovation and expanding healthcare infrastructure.

FAQs

Q: What is the projected growth rate of the oncology drugs market? A: The global oncology drugs market is projected to grow at a CAGR of 12.6% from 2024 to 2031[1].

Q: What are the primary drivers of the demand for PLATINOL-AQ? A: The increasing global incidence of cancer and the adoption of targeted therapies and immunotherapies are primary drivers[1].

Q: What are the major side effects associated with PLATINOL-AQ? A: Major side effects include nephrotoxicity, ototoxicity, and myelosuppression[2][5].

Q: How have launch prices of anticancer drugs changed over time? A: The average launch price of anticancer drugs has increased by 10% annually from 1995 to 2013, adjusted for inflation and health benefits[3].

Q: Which regions are expected to dominate the market for platinum-based drugs? A: North America is anticipated to retain a higher market share due to increased disease prevalence and advanced healthcare infrastructure[4].

Sources

1. Biospace: Oncology Drugs Market to Reach USD 532.91 Billion by 2031[1]
2. RxList: Platinol-AQ (Cisplatin Injection): Side Effects, Uses, Dosage[2]
3. Journal of Economic Perspectives: Pricing in the Market for Anticancer Drugs[3]
4. Allied Market Research: Platinum based Drugs Market Size | Industry Growth By, 2030[4]
5. FDA: Platinol (cisplatin) label[5]